Corticobasal Degeneration (CBD) is a heterogeneous neurodegenerative disorder characterized by asymmetric parkinsonism, apraxia, cortical sensory loss, and alien limb phenomena. Pathologically, CBD is characterized by tau-positive inclusions in neurons and glia, with 4R tau isoforms predominating. Genetic studies have identified MAPT (microtubule-associated protein tau) as the major genetic contributor to CBD risk, with the H1 haplotype being the primary risk factor and specific mutations causing familial cases.
CBD shows significant clinical and pathological overlap with other tauopathies:
- MAPT H1 haplotype: Major risk factor
- Specific MAPT mutations: Cause familial CBD presentations
- Overlap genes: Shared risk with PSP, FTLD-Tau, and PD
- Other genes: Reported associations with DCTN, TGM6
The MAPT H1 haplotype is strongly associated with CBD:
- Prevalence: >95% of CBD patients carry H1/H1 genotype
- Risk: H1/H1 increases CBD risk by 3-8 fold
- Mechanism: Altered tau isoform expression (increased 4R tau)
The H1 haplotype encompasses multiple risk SNPs:
- rs242557
- rs1800547
- rs2471738
Several MAPT mutations cause CBD or CBD-like phenotypes:
The most well-known mutation causing CBD phenotypes:
- Inheritance: Autosomal dominant
- Penetrance: ~90% by age 65
- Phenotype: Classic CBD with prominent cortical symptoms
- Mechanism: Promotes tau aggregation, reduces microtubule binding
Reported in families with CBD features:
- Phenotype: Progressive aphasia and parkinsonism
- Mechanism: Similar to P301L
Affects alternative splicing of exon 10:
- Effect: Increases 4R tau isoform
- Phenotype: CBD or PSP phenotype
¶ R5L and Other Variants
- R5L: Rare variant associated with CBD in some families
- K369I: Reported in families with CBD features
- S305I: Affects exon 10 splicing
DCTN encodes the p150 subunit of dynactin, involved in axonal transport:
- Common variant: p.G59D (autosomal dominant)
- Phenotype: Lower limb-onset parkinsonism with CBD features
- Mechanism: Impaired axonal transport
Variants in TGM6 have been associated with CBD:
- Function: Cross-linking enzyme in neurons
- Mechanism: May affect protein aggregation
- Evidence: GWAS and family studies
CBD shares genetic risk factors with:
- Progressive Supranuclear Palsy (PSP): MAPT H1 haplotype
- Frontotemporal Dementia with Tauopathy (FTLD-Tau): MAPT mutations
- Parkinson's Disease (PD): Some shared loci
GWAS has identified:
- MAPT: Strongest signal
- TMEM106B: Also associated with FTLD
- GRN: Related to TDP-43 pathology
The genetic variants in MAPT lead to tau pathology:
- Isoform imbalance: 4R tau overexpression from H1 haplotype
- Hyperphosphorylation: Abnormal tau phosphorylation
- Aggregation: Formation of tau filaments
- Neuronal loss: Cortical and basal ganglia degeneration
- Microtubule dysfunction: Loss of tau's microtubule-stabilizing function
- Axonal transport impairment: Affected by tau pathology
- Synaptic dysfunction: Early synaptic changes
- Glial involvement: Astrocyte and microglia activation
CBD shows pathological overlap with:
- PSP (4R tau inclusions)
- FTLD-Tau (frontotemporal atrophy patterns)
- PD (in some cases, alpha-synuclein co-pathology)
Genetic testing for CBD is considered in:
- Early-onset patients (<60 years)
- Patients with family history
- Atypical presentations with cortical features
Testing typically includes:
- MAPT haplotype analysis
- Targeted MAPT mutation screening
- DCTN analysis if indicated
- Autosomal dominant inheritance for mutations
- Variable expressivity
- Importance for family screening
-
Tau-targeted therapies:
- Anti-tau antibodies
- Tau aggregation inhibitors
- Kinase inhibitors
-
Gene therapy approaches:
- MAPT silencing via AAV
- Modulation of splicing factors
-
Symptomatic treatments:
- Limited response to dopaminergic therapy
- Physical/occupational therapy
- Speech therapy for dysarthria
The study of Cbd Genetic Variants has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Dickson DW, et al. Neuropathology of variants of progressive supranuclear palsy and corticobasal degeneration. J Neurol. 2010;257(4):569-575.
- Hoglinger GU, et al. Identification of common genetic risk variants for progressive supranuclear palsy. Nat Genet. 2011;43(7):699-705.
- Litvan I, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80(5):496-503.
- Spina S, et al. Frontotemporal dementia with corticobasal syndrome phenotype due to C9orf72 repeat expansion. Neurology. 2017;89(2):e19-e25.
- Lee SE, et al. Clinicopathological correlations in corticobasal degeneration: improving the diagnostic approach. Neurology. 2011;76(8):714-722.